

Jose M Garcia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4428400/publications.pdf>

Version: 2024-02-01

56
papers

3,342
citations

218592

26
h-index

155592

55
g-index

58
all docs

58
docs citations

58
times ranked

4647
citing authors

#	ARTICLE	IF	CITATIONS
1	The Small Molecule Nobiletin Targets the Molecular Oscillator to Enhance Circadian Rhythms and Protect against Metabolic Syndrome. <i>Cell Metabolism</i> , 2016, 23, 610-621.	7.2	380
2	Sarcopenia, Cachexia and Aging: Diagnosis, Mechanisms and Therapeutic Options - A Mini-Review. <i>Gerontology</i> , 2014, 60, 294-305.	1.4	338
3	Characterization of Adult Ghrelin and Ghrelin Receptor Knockout Mice under Positive and Negative Energy Balance. <i>Endocrinology</i> , 2008, 149, 843-850.	1.4	235
4	Active Ghrelin Levels and Active to Total Ghrelin Ratio in Cancer-Induced Cachexia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 2920-2926.	1.8	222
5	Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. <i>Lancet Oncology</i> , The, 2015, 16, 108-116.	5.1	176
6	Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2015, 6, 132-143.	2.9	165
7	Sex Differences in Muscle Wasting. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1043, 153-197.	0.8	145
8	Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. <i>Supportive Care in Cancer</i> , 2013, 21, 129-137.	1.0	141
9	Effect on Body Weight and Safety of RC1291, a Novel, Orally Available Ghrelin Mimetic and Growth Hormone Secretagogue: Results of a Phase I, Randomized, Placebo-Controlled, Multiple-Dose Study in Healthy Volunteers. <i>Oncologist</i> , 2007, 12, 594-600.	1.9	115
10	Ghrelin Prevents Cisplatin-Induced Mechanical Hyperalgesia and Cachexia. <i>Endocrinology</i> , 2008, 149, 455-460.	1.4	112
11	Low Testosterone Levels and Increased Inflammatory Markers in Patients with Cancer and Relationship with Cachexia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E700-E709.	1.8	91
12	Hypogonadism in male patients with cancer. <i>Cancer</i> , 2006, 106, 2583-2591.	2.0	88
13	Inhibition of Cisplatin-Induced Lipid Catabolism and Weight Loss by Ghrelin in Male Mice. <i>Endocrinology</i> , 2013, 154, 3118-3129.	1.4	87
14	Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2012, 3, 245-251.	2.9	77
15	Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. <i>Growth Hormone and IGF Research</i> , 2009, 19, 267-273.	0.5	76
16	Circulating Inflammatory Cytokines and Adipokines Are Associated With Increased Risk of Barrett's Esophagus: A Case-Control Study. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 229-238.e3.	2.4	71
17	Macimorelin as a Diagnostic Test for Adult GH Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3083-3093.	1.8	71
18	Toll-like receptor 4 mediates Lewis lung carcinoma-induced muscle wasting via coordinate activation of protein degradation pathways. <i>Scientific Reports</i> , 2017, 7, 2273.	1.6	69

#	ARTICLE	IF	CITATIONS
19	A Multibiomarker Risk Score Helps Predict Risk for Barrett's Esophagus. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1267-1271.	2.4	66
20	Rise of Plasma Ghrelin With Weight Loss is Not Sustained During Weight Maintenance. <i>Obesity</i> , 2006, 14, 1716-1723.	1.5	54
21	Use of growth hormone, IGF-I, and insulin for anabolic purpose: Pharmacological basis, methods of detection, and adverse effects. <i>Molecular and Cellular Endocrinology</i> , 2018, 464, 65-74.	1.6	49
22	Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1245-1253.	0.9	45
23	Is there an effect of ghrelin/ghrelin analogs on cancer? A systematic review. <i>Endocrine-Related Cancer</i> , 2016, 23, R393-R409.	1.6	43
24	Update on Management of Cancer-Related Cachexia. <i>Current Oncology Reports</i> , 2017, 19, 3.	1.8	43
25	Elimination of Age-Associated Hepatic Steatosis and Correction of Aging Phenotype by Inhibition of cdk4-C/EBP β -p300 Axis. <i>Cell Reports</i> , 2018, 24, 1597-1609.	2.9	35
26	Ghrelin deletion protects against age-associated hepatic steatosis by downregulating the C/EBP β -p300/DGAT1 pathway. <i>Aging Cell</i> , 2018, 17, e12688.	3.0	32
27	Clinical development of ghrelin axis-derived molecules for cancer cachexia treatment. <i>Current Opinion in Supportive and Palliative Care</i> , 2013, 7, 368-375.	0.5	27
28	Ghrelin Partially Protects Against Cisplatin-Induced Male Murine Gonadal Toxicity in a GHSR-1a-Dependent Manner. <i>Biology of Reproduction</i> , 2015, 92, 76.	1.2	26
29	Deletion of ghrelin prevents aging-associated obesity and muscle dysfunction without affecting longevity. <i>Aging Cell</i> , 2017, 16, 859-869.	3.0	26
30	Ghrelin Prevents Cisplatin-Induced Testicular Damage by Facilitating Repair of DNA Double Strand Breaks Through Activation of p53 in Mice. <i>Biology of Reproduction</i> , 2015, 93, 24.	1.2	25
31	Preoperative cancer cachexia and short-term outcomes following surgery. <i>Journal of Surgical Research</i> , 2016, 205, 398-406.	0.8	22
32	Whole-body and adipose tissue metabolic phenotype in cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 1124-1133.	2.9	17
33	What is next after anamorelin?. <i>Current Opinion in Supportive and Palliative Care</i> , 2017, 11, 266-271.	0.5	16
34	Evaluation of physical function and its association with body composition, quality of life and biomarkers in cancer cachexia patients. <i>Clinical Nutrition</i> , 2021, 40, 978-986.	2.3	16
35	Cancer-driven changes link T cell frequency to muscle strength in people with cancer: a pilot study. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 827-843.	2.9	15
36	Evaluation of Veterans MOVE! Program for Weight Loss. <i>Journal of Nutrition Education and Behavior</i> , 2016, 48, 299-303.e1.	0.3	14

#	ARTICLE	IF	CITATIONS
37	A bladder cancer patient-derived xenograft displays aggressive growth dynamics in vivo and in organoid culture. <i>Scientific Reports</i> , 2021, 11, 4609.	1.6	14
38	Ghrelin ameliorates tumor-induced adipose tissue atrophy and inflammation via Ghrelin receptor-dependent and -independent pathways. <i>Oncotarget</i> , 2020, 11, 3286-3302.	0.8	14
39	The habenula as a novel link between the homeostatic and hedonic pathways in cancer-associated weight loss: a pilot study. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 497-504.	2.9	12
40	Assessing Cachexia Acutely after Autologous Stem Cell Transplant. <i>Cancers</i> , 2019, 11, 1300.	1.7	11
41	Growth hormone secretagogue receptor-1a mediates ghrelin's effects on attenuating tumour-induced loss of muscle strength but not muscle mass. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 1280-1295.	2.9	8
42	Editorial: Neuroendocrine Disorders After Traumatic Brain Injury: Past, Present and Future. <i>Frontiers in Endocrinology</i> , 2019, 10, 386.	1.5	7
43	Appendicular Lean Mass, Grip Strength, and the Development of Hospital-Associated Activities of Daily Living Disability Among Older Adults in the Health ABC Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2022, 77, 1398-1404.	1.7	7
44	Cannabinoids in Patients with Nausea and Vomiting Associated with Malignancy and Its Treatments. <i>American Journal of Medicine</i> , 2018, 131, 755-759.e2.	0.6	6
45	Muscle mass, not radiodensity, predicts physical function in cancer patients with or without cachexia. <i>Oncotarget</i> , 2020, 11, 1911-1921.	0.8	6
46	Off-Label Megestrol in Patients with Anorexia-Cachexia Syndrome Associated with Malignancy and Its Treatments. <i>American Journal of Medicine</i> , 2018, 131, 623-629.e1.	0.6	5
47	Experience of a Pituitary Clinic for US Military Veterans With Traumatic Brain Injury. <i>Journal of the Endocrine Society</i> , 2021, 5, bvab005.	0.1	5
48	Omega-3 Fatty Acids in Patients with Anorexia-Cachexia Syndrome Associated with Malignancy and Its Treatments. <i>American Journal of Medicine</i> , 2017, 130, 1151-1155.	0.6	4
49	Management of Opioid-Induced Constipation in Patients with Malignancy. <i>American Journal of Medicine</i> , 2018, 131, 1041-1051.e3.	0.6	3
50	Androgens and estrogens predict sexual function after autologous hematopoietic stem cell transplant in men. <i>Andrology</i> , 2022, 10, 291-302.	1.9	3
51	Nonsteroidal Anti-Inflammatory Drugs in Patients with Anorexia-Cachexia Syndrome Associated with Malignancy and Its Treatments. <i>American Journal of Medicine</i> , 2017, 130, 1033-1036.	0.6	2
52	Gout and open-angle glaucoma risk in a veteran population. <i>Graefes' Archive for Clinical and Experimental Ophthalmology</i> , 2021, 259, 3371-3379.	1.0	2
53	High-Dose Benzodiazepine Therapy in Hospitalized Anxious Patients. <i>Journal of Clinical Pharmacology</i> , 1983, 23, 100-105.	1.0	1
54	Reversible Adrenal Insufficiency in Three Patients With Post-Roux-en-Y Gastric Bypass Noninsulinoma Pancreatogenous Hypoglycemia Syndrome. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2014, 2, 232470961452699.	0.3	1

#	ARTICLE	IF	CITATIONS
55	Clinical research in older adults with hematologic malignancies: Opportunities for alignment in the Veterans Affairs. <i>Seminars in Oncology</i> , 2019, 46, 341-345.	0.8	0
56	Testosterone replacement for fatigue in male hypogonadic patients with advanced cancer: A preliminary double-blind placebo-controlled trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, e19643-e19643.	0.8	0